ProCE Banner Activity

Keeping Pace With Rapid Changes in the Management of RCC

Clinical Thought

The following commentary is adapted from an ASCO 2023 satellite symposium on RCC providing practical up-to-date insight on how to best manage patients with RCC in the context of rapid clinical changes.

Released: July 19, 2023

Share

Faculty

Katy Beckermann

Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Stephanie A. Berg

Stephanie A. Berg, DO

Instructor of Medicine
Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Toni K. Choueiri

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts 

Provided by

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AVEO Pharmaceuticals, Inc. (“AVEO Oncology”) and Eisai. Supported by a medical education grant from Exelixis, Inc.

AVEO Pharmaceuticals, Inc.

Eisai

Exelixis, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Katy Beckermann, MD, PhD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Katy Beckermann, MD, PhD: researcher (paid to institution): Aravive, Arsenal Bio, Bristol Myers Squibb-IASCL-LCFA, Pionyr; consultant/advisor/speaker: Aravive, Arcus, Alpine Bioscience, Aveo, Bristol Myers Squibb, Eisai, Exelixis, Merck, Nimbus, Xencor.

Stephanie A. Berg, DO

Instructor of Medicine
Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Stephanie A. Berg, DO: consultant/advisor/speaker: Bristol Myers Squibb, Eisai, Exelexis.

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts 

Toni K. Choueiri, MD: consultant/advisor/speaker: Bristol Myers Squibb, EMD Serono, Exelixis/Ipsen, Merck, MJH Life Sciences, Pfizer, Roche.